Vimarsana
Biggest News Aggregation in the World

Chronic Headache News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chronic Headache. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chronic Headache Today - Breaking & Trending Today

EHC 2023: Medication Overuse Headache a Pain to Treat - Vimarsana News

EHC 2023: Medication Overuse Headache a Pain to Treat

Medication overuse headache is a common secondary order condition whose treatment requires behavioral intervention and education.

Childhood Trauma Linked to Adult Headache - Vimarsana News

Childhood Trauma Linked to Adult Headache

Adverse childhood experiences, including physical abuse and neglect, were found to be important risk factors for adult primary headache disorders.

Opioids May Be Overused in Acute Treatment of Migraine - Vimarsana News

Opioids May Be Overused in Acute Treatment of Migraine

A retrospective observational study of three migraine cohorts in Canada suggests that acute medications, particularly opioids, are overused and that preventive medications are underused.

Intravenous dihydroergotamine safe for refractory chronic migraine - Vimarsana News

Intravenous dihydroergotamine safe for refractory chronic migraine

1. Intravenous dihydroergotamine (DHE) was found in this retrospective study to be an effective therapeutic option for refractory chronic migraine. 2. DHE was additionally safe for individuals with elevated risk for cardiovascular events and other cardiovascular risk factors. Evidence Rating Level: 2 (Good) Chronic migraine is a debilitating condition that severely impacts the quality of

Atogepant may be safe and effective for prevention of chronic migraines - Vimarsana News

Atogepant may be safe and effective for prevention of chronic migraines

1. Monthly migraine days were significantly reduced in atogepant 30 mg twice daily and atogepant 60 mg once daily groups compared to placebo. 2. The frequency of acute medication use for headaches was reduced among patients receiving atogepant compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Migraine is a chronic neurological disease affecting